BRPI0907729A2 - Métodos para tratar doenças mediadas pela catepsina b em um mamífero e para tratar um indivíduo diagnosticado tanto com hcv quanto com fribose em um mamífero - Google Patents
Métodos para tratar doenças mediadas pela catepsina b em um mamífero e para tratar um indivíduo diagnosticado tanto com hcv quanto com fribose em um mamíferoInfo
- Publication number
- BRPI0907729A2 BRPI0907729A2 BRPI0907729-4A BRPI0907729A BRPI0907729A2 BR PI0907729 A2 BRPI0907729 A2 BR PI0907729A2 BR PI0907729 A BRPI0907729 A BR PI0907729A BR PI0907729 A2 BRPI0907729 A2 BR PI0907729A2
- Authority
- BR
- Brazil
- Prior art keywords
- mammal
- treating
- fribose
- hcv
- methods
- Prior art date
Links
- 241000124008 Mammalia Species 0.000 title 2
- 102000005600 Cathepsins Human genes 0.000 title 1
- 108010084457 Cathepsins Proteins 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 230000001404 mediated effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Virology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Ophthalmology & Optometry (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Communicable Diseases (AREA)
- Pain & Pain Management (AREA)
- Molecular Biology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2700708P | 2008-02-07 | 2008-02-07 | |
| PCT/US2009/033229 WO2009100225A1 (en) | 2008-02-07 | 2009-02-05 | Inhibitors of cathepsin b |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0907729A2 true BRPI0907729A2 (pt) | 2015-07-14 |
Family
ID=40939419
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0907729-4A BRPI0907729A2 (pt) | 2008-02-07 | 2009-02-05 | Métodos para tratar doenças mediadas pela catepsina b em um mamífero e para tratar um indivíduo diagnosticado tanto com hcv quanto com fribose em um mamífero |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US8211897B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2237793A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP5718647B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN101969973B (cg-RX-API-DMAC7.html) |
| BR (1) | BRPI0907729A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2713108A1 (cg-RX-API-DMAC7.html) |
| EA (1) | EA201001262A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2010008371A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2009100225A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7932277B2 (en) | 2007-05-10 | 2011-04-26 | Intermune, Inc. | Peptide inhibitors of hepatitis C virus replication |
| EA201071034A1 (ru) | 2008-04-15 | 2011-06-30 | Интермьюн, Инк. | Новые макроциклические ингибиторы репликаций вируса гепатита с |
| AR075584A1 (es) | 2009-02-27 | 2011-04-20 | Intermune Inc | COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO. |
| CN103946213A (zh) * | 2011-11-25 | 2014-07-23 | 霍夫曼-拉罗奇有限公司 | 作为组织蛋白酶抑制剂的新吡咯烷衍生物 |
| WO2014164844A1 (en) * | 2013-03-11 | 2014-10-09 | Virobay, Inc. | Cathepsin inhibitors |
| BR112018012914B1 (pt) | 2015-12-22 | 2023-04-18 | SHY Therapeutics LLC | Composto, uso de um composto e composição farmacêutica |
| KR102595723B1 (ko) | 2016-06-21 | 2023-10-27 | 오리온 옵탈몰로지 엘엘씨 | 헤테로시클릭 프롤린아미드 유도체 |
| WO2017222914A1 (en) | 2016-06-21 | 2017-12-28 | Inception 4, Inc. | Carbocyclic prolinamide derivatives |
| JP2019526563A (ja) * | 2016-08-23 | 2019-09-19 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | Htra1阻害剤としての新規ジフルオロケタミド誘導体 |
| US10834908B2 (en) * | 2017-04-26 | 2020-11-17 | InfiCure Bio AB | Model animal for fibrosis |
| AU2018288841B2 (en) | 2017-06-21 | 2022-09-29 | SHY Therapeutics LLC | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, Rasopathies, and fibrotic disease |
| CN111447940A (zh) * | 2017-07-17 | 2020-07-24 | 科罗拉多大学评议会 | 预防或治疗由辐射或放射疗法引起的辐射诱发的旁观者效应的组合物和方法 |
| WO2020132071A1 (en) | 2018-12-19 | 2020-06-25 | Shy Therapeutics. Llc | Compounds that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and f1brotic disease |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20000286A2 (en) | 1997-11-11 | 2000-12-31 | Pfizer Prod Inc | Thienopyrimidine and thienopyridine derivatives useful as anticancer agents |
| US6404397B1 (en) | 1998-08-10 | 2002-06-11 | Raytheon Company | Compact all-weather electromagnetic imaging system |
| US6323180B1 (en) * | 1998-08-10 | 2001-11-27 | Boehringer Ingelheim (Canada) Ltd | Hepatitis C inhibitor tri-peptides |
| US6608027B1 (en) | 1999-04-06 | 2003-08-19 | Boehringer Ingelheim (Canada) Ltd | Macrocyclic peptides active against the hepatitis C virus |
| EP1254901A4 (en) * | 2000-01-26 | 2003-03-05 | Ono Pharmaceutical Co | 5-CHAIN CYCLIC COMPOUNDS, CONTAINING NITROGEN, AND MEDICINAL PRODUCTS CONTAINING THE SAME AS ACTIVE INGREDIENTS |
| CA2369970A1 (en) | 2002-02-01 | 2003-08-01 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis c inhibitor tri-peptides |
| ATE500264T1 (de) | 2003-09-22 | 2011-03-15 | Boehringer Ingelheim Int | Makrozyklische peptide mit wirkung gegen das hepatitis-c-virus |
| WO2006113942A2 (en) | 2005-04-20 | 2006-10-26 | Schering Corporation | Method of inhibiting cathepsin activity |
| WO2006130552A2 (en) | 2005-06-02 | 2006-12-07 | Schering Corporation | Methods of treating hepatitis c virus |
| US20060287248A1 (en) | 2005-06-02 | 2006-12-21 | Schering Corporation | Asymmetric dosing methods |
| WO2006130554A2 (en) | 2005-06-02 | 2006-12-07 | Schering Corporation | Methods of treating hepatitis c virus |
| US7608592B2 (en) * | 2005-06-30 | 2009-10-27 | Virobay, Inc. | HCV inhibitors |
| RU2008152171A (ru) * | 2006-07-05 | 2010-08-10 | Интермьюн, Инк. (Us) | Новые ингибиторы вирусной репликации гепатита с |
| US20080161254A1 (en) | 2007-01-03 | 2008-07-03 | Virobay, Inc. | Hcv inhibitors |
-
2009
- 2009-02-05 CN CN200980109079.9A patent/CN101969973B/zh not_active Expired - Fee Related
- 2009-02-05 CA CA2713108A patent/CA2713108A1/en not_active Abandoned
- 2009-02-05 JP JP2010545997A patent/JP5718647B2/ja active Active
- 2009-02-05 MX MX2010008371A patent/MX2010008371A/es active IP Right Grant
- 2009-02-05 WO PCT/US2009/033229 patent/WO2009100225A1/en not_active Ceased
- 2009-02-05 US US12/366,504 patent/US8211897B2/en not_active Expired - Fee Related
- 2009-02-05 BR BRPI0907729-4A patent/BRPI0907729A2/pt not_active IP Right Cessation
- 2009-02-05 EA EA201001262A patent/EA201001262A1/ru unknown
- 2009-02-05 EP EP09709414.8A patent/EP2237793A4/en not_active Withdrawn
-
2014
- 2014-10-10 JP JP2014209108A patent/JP2015051985A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| US20090203629A1 (en) | 2009-08-13 |
| JP2015051985A (ja) | 2015-03-19 |
| EA201001262A1 (ru) | 2011-04-29 |
| WO2009100225A1 (en) | 2009-08-13 |
| EP2237793A1 (en) | 2010-10-13 |
| JP2011511089A (ja) | 2011-04-07 |
| CN101969973A (zh) | 2011-02-09 |
| JP5718647B2 (ja) | 2015-05-13 |
| CA2713108A1 (en) | 2009-08-13 |
| US8211897B2 (en) | 2012-07-03 |
| CN101969973B (zh) | 2015-07-22 |
| EP2237793A4 (en) | 2013-07-31 |
| MX2010008371A (es) | 2010-10-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0907729A2 (pt) | Métodos para tratar doenças mediadas pela catepsina b em um mamífero e para tratar um indivíduo diagnosticado tanto com hcv quanto com fribose em um mamífero | |
| BRPI0910608A2 (pt) | métodos e sistemas para avaliar resultados clínicos | |
| BRPI0920827A2 (pt) | Evento transgênico da soja mon87705 e métodos para detecção do mesmo | |
| EP2178591A4 (en) | TRACHEOSTOMA VALVES AND CORRESPONDING METHODS | |
| FI20085839A0 (fi) | Menetelmiä ja välineitä pehmytkudosteknologiaan | |
| BRPI0807225A2 (pt) | Dispositivo e método endocirúrgico | |
| NO20101523L (no) | Innvendig ventiltrehette og setteverktøy for innvendig ventiltrehette | |
| BRPI0906432A2 (pt) | Laminado elástico e método de fabricação | |
| BRPI0814330A2 (pt) | métodos e kits cirúrgicos | |
| BRPI0816907A2 (pt) | Método e dispositivo | |
| BRPI0921726A2 (pt) | método e dispositivo para ativar células tronco | |
| EP2484190A4 (en) | COOLING PLATE WITH PENS | |
| BRPI0920166A2 (pt) | conjuntos para reparo de alimentos e métodos relacionados | |
| BRPI0916492A2 (pt) | dispositivo e método para detectar depósitos | |
| BRPI0918353A2 (pt) | máscaras faciais em dobras planas e pregueadas | |
| NO20080909L (no) | Gate valve actuator and method | |
| FI20065359L (fi) | Menetelmä ja rannelaite | |
| DE502007002963D1 (de) | Messvertärkungsvorrichtung und -verfahren | |
| BRPI0907150A2 (pt) | Dispositivo e método para microelastografia | |
| FI20065734L (fi) | Laite ja menetelmä suorituksen seuraamiseksi | |
| DK2285935T5 (da) | Forkulningsmetode og -anordning | |
| DK2131682T3 (da) | Autoklave og fremgangsmåde | |
| BRPI0716320A2 (pt) | Método para reduzir a absorção de fosfato em um individuo animal humano e não- humano e método para reduzir a absorção de fosfato em um individuo humano | |
| DE602007005030D1 (de) | Supraleitender Elektromagnet | |
| BRPI0918279A2 (pt) | método de diagnóstico e kit de diagnóstico para dermatomiosite |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 8A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |